Cargando…

NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib

Anlotinib treatment of non-small cell lung cancer (NSCLC) is hindered by drug insensitivity. Downregulation of long non-coding RNA (lncRNA) NEAT1 can suppress the proliferation and invasion by NSCLC cells. This study explored the role of the combination of anlotinib with NEAT1 knockdown on NSCLC pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Guoqing, Hu, Chenxi, Hui, Kaiyuan, Chen, Ting, Zhang, Huiqin, Jiang, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202848/ https://www.ncbi.nlm.nih.gov/pubmed/33982669 http://dx.doi.org/10.18632/aging.203004

Ejemplares similares

Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
por: Gu, Guoqing, et al.
Publicado: (2021)

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
por: Liang, Lijun, et al.
Publicado: (2019)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Effects of combined inhibition of STAT3 and VEGFR2 pathways on the radiosensitivity of non-small-cell lung cancer cells
por: Hu, Chenxi, et al.
Publicado: (2019)

Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2019)

Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
por: Liu, Liang, et al.
Publicado: (2021)

NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells
por: Jiang, Pan, et al.
Publicado: (2016)

Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

Long non-coding RNA NEAT1 regulates ferroptosis sensitivity in non-small-cell lung cancer
por: Wu, Hongxia, et al.
Publicado: (2021)

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
por: Han, Dong, et al.
Publicado: (2022)

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma
por: Hu, Yuliang, et al.
Publicado: (2018)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer
por: Chen, Jingyu, et al.
Publicado: (2022)

Knockdown of NEAT1 induces tolerogenic phenotype in dendritic cells by inhibiting activation of NLRP3 inflammasome
por: Zhang, Maomao, et al.
Publicado: (2019)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis
por: Yu, Guocan, et al.
Publicado: (2021)

The role and significance of VEGFR2(+) regulatory T cells in tumor immunity
por: Zhu, Panrong, et al.
Publicado: (2017)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
por: Lu, Jun, et al.
Publicado: (2019)

Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer
por: Fang, Shencun, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhang, Kun, et al.
Publicado: (2020)

Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis
por: Yu, Guocan, et al.
Publicado: (2020)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
por: Wu, Ying, et al.
Publicado: (2023)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Knockdown of PLAT enhances the anticancer effect of gefitinib in non-small cell lung cancer
por: Yan, Mengnan, et al.
Publicado: (2020)

Combined neat model for the prognosis of postoperative stage III‐N2 non‐small cell lung cancer
por: Zhai, Yirui, et al.
Publicado: (2020)

miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib
por: Wang, Leisheng, et al.
Publicado: (2019)

TRIAP1 knockdown sensitizes non‐small cell lung cancer to ionizing radiation by disrupting redox homeostasis
por: Hao, Chun‐cheng, et al.
Publicado: (2020)

Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial
por: Deng, Pengbo, et al.
Publicado: (2022)

Correction: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
por: Lu, Jun, et al.
Publicado: (2022)

Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer
por: Hou, Xiao-Ming, et al.
Publicado: (2019)

Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e
por: Gong, Wei, et al.
Publicado: (2016)

Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Xiang, Yi, et al.
Publicado: (2022)

Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
por: Gan, Yuying, et al.
Publicado: (2021)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhong, Qiuxia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ei5te9kdb71p1tq11i46vj5ie7